Actively Recruiting
Randomised Controlled Trial Of Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)
Led by National Healthcare Group Polyclinics · Updated on 2026-03-20
240
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
N
National Healthcare Group Polyclinics
Lead Sponsor
N
National Medical Research Council (NMRC), Singapore
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to compare usual care with biomarker-directed care using blood eosinophil counts for managing patients with mild to moderate asthma in a primary care setting. The goal is to evaluate whether guiding asthma treatment by blood eosinophil count can reduce asthma attacks, improve symptom control, and enhance quality of life compared to standard care. The study is sponsored by the National Healthcare Group Polyclinics and focuses on adults aged 21 to 65 with asthma. Participants are randomly assigned to one of two groups: one group receives asthma management guided by blood eosinophil counts (biomarker-directed treatment), while the control group receives usual care without the use of this biomarker. Treatment follows the Global Initiative for Asthma (GINA) 2025 guidelines for mild to moderate asthma (steps 1 to 3). The study includes approximately one year of follow-up with visits about every four months. During the study, researchers will monitor the time to the first asthma attack requiring hospitalization, the number of non-hospitalized asthma exacerbations, and worsening of asthma symptoms over 12 months. They will also assess quality of life, asthma control, lung function tests, and healthcare visits related to asthma. Participants must be able to attend scheduled appointments and provide informed consent, with safety and adherence monitored throughout the study period.
CONDITIONS
Brief Title
Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Singaporeans or Singapore Permanent Residents
- Patients aged 21 to 65 years old
- Physician diagnosed asthma for at least 4 weeks
- On or will be started on Global Initiative for Asthma (GINA) 2025 step 1 to 3 treatment
- No asthma exacerbations in the 4 weeks before randomisation
- Able and willing to attend study appointments approximately every 4 months for 1 year
- Able to provide informed consent
- Stable cardiovascular status with controlled hypertension and no active heart disease or arrhythmias
You will not qualify if you...
- History of life-threatening asthma requiring intubation or intensive care
- Severe or difficult to treat asthma
- Current use of long-term immunosuppression, Montelukast, Theophylline, or long-term oral steroids
- Known causes of eosinophilia other than asthma (e.g., parasitic infection) as judged by physician
- Current use of beta-blocking agents including eye-drops
- Use of oral, rectal, or parenteral glucocorticoids within 30 days or depot glucocorticoids within 12 weeks prior to recruitment
- Diagnosis of Chronic Obstructive Pulmonary Disease, Interstitial lung disease, or bronchiectasis
- Significant other diseases or disorders that increase risk or affect participation or study results
- Current enrollment in another asthma interventional clinical trial
- Female participants who are pregnant or planning pregnancy during the study
- Planned travel outside the country for 16 or more consecutive weeks during the study
- Investigator's assessment of poor ability to follow study instructions or procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receive asthma management guided by blood eosinophil count or usual asthma care in primary care.
Visits approximately every 4 months for 1 year
Trial Site Locations
Total: 1 location
1
National Healthcare Group Polyclinics
Singapore, Singapore, 308205
Actively Recruiting
Research Team
W
Wern Ee Tang
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here